141 related articles for article (PubMed ID: 14569063)
1. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam.
Cummins CL; Jacobsen W; Christians U; Benet LZ
J Pharmacol Exp Ther; 2004 Jan; 308(1):143-55. PubMed ID: 14569063
[TBL] [Abstract][Full Text] [Related]
2. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Cummins CL; Jacobsen W; Benet LZ
J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
[TBL] [Abstract][Full Text] [Related]
3. New insights into drug absorption: studies with sirolimus.
Paine MF; Leung LY; Watkins PB
Ther Drug Monit; 2004 Oct; 26(5):463-7. PubMed ID: 15385826
[TBL] [Abstract][Full Text] [Related]
4. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model.
Cummins CL; Salphati L; Reid MJ; Benet LZ
J Pharmacol Exp Ther; 2003 Apr; 305(1):306-14. PubMed ID: 12649383
[TBL] [Abstract][Full Text] [Related]
5. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes.
Benet LZ; Cummins CL; Wu CY
Int J Pharm; 2004 Jun; 277(1-2):3-9. PubMed ID: 15158963
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion.
Paine MF; Leung LY; Lim HK; Liao K; Oganesian A; Zhang MY; Thummel KE; Watkins PB
J Pharmacol Exp Ther; 2002 Apr; 301(1):174-86. PubMed ID: 11907172
[TBL] [Abstract][Full Text] [Related]
8. Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate.
Cummins CL; Mangravite LM; Benet LZ
Pharm Res; 2001 Aug; 18(8):1102-9. PubMed ID: 11587480
[TBL] [Abstract][Full Text] [Related]
9. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells.
Gan LS; Moseley MA; Khosla B; Augustijns PF; Bradshaw TP; Hendren RW; Thakker DR
Drug Metab Dispos; 1996 Mar; 24(3):344-9. PubMed ID: 8820426
[TBL] [Abstract][Full Text] [Related]
10. Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase.
Hu M; Li Y; Davitt CM; Huang SM; Thummel K; Penman BW; Crespi CL
Pharm Res; 1999 Sep; 16(9):1352-9. PubMed ID: 10496649
[TBL] [Abstract][Full Text] [Related]
11. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918.
Wu CY; Benet LZ
Drug Metab Dispos; 2003 Nov; 31(11):1292-5. PubMed ID: 14570757
[TBL] [Abstract][Full Text] [Related]
12. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data.
Benet LZ; Cummins CL; Wu CY
Curr Drug Metab; 2003 Oct; 4(5):393-8. PubMed ID: 14529371
[TBL] [Abstract][Full Text] [Related]
13. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
Patel J; Buddha B; Dey S; Pal D; Mitra AK
Am J Ther; 2004; 11(4):262-77. PubMed ID: 15266218
[TBL] [Abstract][Full Text] [Related]
14. Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein.
Huang Y; Okochi H; May BC; Legname G; Prusiner SB; Benet LZ; Guglielmo BJ; Lin ET
Drug Metab Dispos; 2006 Jul; 34(7):1136-44. PubMed ID: 16581945
[TBL] [Abstract][Full Text] [Related]
15. Transport and uptake of clausenamide enantiomers in CYP3A4-transfected Caco-2 cells: An insight into the efflux-metabolism alliance.
Hua F; Shi MJ; Zhu XL; Li M; Wang HX; Yu XM; Li Y; Zhu CJ
Biochem Pharmacol; 2015 Nov; 98(1):224-30. PubMed ID: 26301745
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.
Yalkinoglu Ö; Becker A; Krebs-Brown A; Vetter C; Lüpfert C; Perrin D; Heuer J; Biedert H; Hirt S; Bytyqi A; Bachmann A; Strotmann R
Invest New Drugs; 2023 Aug; 41(4):596-605. PubMed ID: 37415001
[TBL] [Abstract][Full Text] [Related]
17. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4.
Hochman JH; Chiba M; Nishime J; Yamazaki M; Lin JH
J Pharmacol Exp Ther; 2000 Jan; 292(1):310-8. PubMed ID: 10604964
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4.
Hochman JH; Chiba M; Yamazaki M; Tang C; Lin JH
J Pharmacol Exp Ther; 2001 Jul; 298(1):323-30. PubMed ID: 11408558
[TBL] [Abstract][Full Text] [Related]
19. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
Zhang Y; Guo X; Lin ET; Benet LZ
Drug Metab Dispos; 1998 Apr; 26(4):360-6. PubMed ID: 9531525
[TBL] [Abstract][Full Text] [Related]
20. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Becquemont L; Glaeser H; Drescher S; Hitzl M; Simon N; Murdter TE; Heinkele G; Hofmann U; Schaefer C; Burk O; Verstuyft C; Eichelbaum M; Fromm MF
Clin Pharmacol Ther; 2006 May; 79(5):449-60. PubMed ID: 16678547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
